Tafamidis is now in the market for the treatment of TTR related amyloidoses and other compounds are in clinical trials such as acoramidis (Judge et al., 2019) or in the pipeline for being tested in clinical studies (Corazza et al., 2019). The gene discussed is TTR; the disease is amyloidosis.